CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $81.96M, lower than 95% of all stocks globally
- PositionDebt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.07×)
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
81.96MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.9330xvs all stocks
52-Week Change
-63.86%vs all stocks
Market Capitalization
81.96MUSDvs all stocks (USD)
Enterprise Value
7.47MUSDvs all stocks (USD)
Forward P/E
-1.44xvs Biotechnology peers
Price to Book (MRQ)
0.9462xvs Biotechnology peers
Enterprise to EBITDA
-0.1420xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-37.70%vs Biotechnology peers
Return on Equity (TTM)
-59.80%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Aug 28, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
0.00USDvs all stocks (USD)
Net Income (TTM)
-64.86MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-46.03MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-24.05MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Aug 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-56.38MUSDvs all stocks (USD)
Pre-tax Income
-52.60MUSDFY2025 · Dec 31, 2025Net Income
-52.60MUSDFY2025 · Dec 31, 2025EBIT
-52.60MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-52.60MUSDFY2025 · Dec 31, 2025Research & Development
32.67MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
23.71MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
3.82MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
0.00USDFY2025 · Dec 31, 2025EPS (Basic)
-1.34USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.34USDFY2025 · Dec 31, 2025Basic Shares Outstanding
39.22MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
39.22MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-52.60MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-30.55MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
97.56MUSDFY2025 · Dec 31, 2025Interest Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-52.60MUSDFY2025 · Dec 31, 2025Stock-based Compensation
19.16MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
2.88MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
0.00USDFY2025 · Dec 31, 2025Shares Outstanding
26.53MSharesUpdated Aug 28, 2026Shares Short
5.47MSharesUpdated Aug 28, 2026Short Ratio
0.8400daysvs all stocks
Short % of Shares Outstanding
14.75%vs all stocks
% Held by Insiders
0.11%vs all stocks
% Held by Institutions
90.31%vs all stocks
Total Cash (MRQ)
117.98MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.06USDUpdated Aug 28, 2026Total Debt (MRQ)
0.00USDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
15.07xvs Biotechnology peers
Book Value per Share (MRQ)
2.29USDUpdated Aug 28, 2026Total Assets
104.23MUSDvs all stocks (USD)
Total Current Assets
104.23MUSDFY2025 · Dec 31, 2025Total Liabilities
7.16MUSDFY2025 · Dec 31, 2025Total Non-current Assets
0.00USDFY2025 · Dec 31, 2025Total Non-current Liabilities
0.00USDFY2025 · Dec 31, 2025Total Current Liabilities
7.16MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
97.56MUSDFY2025 · Dec 31, 2025Accounts Payable
6.04MUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-367.45MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
97.07MUSDvs all stocks (USD)
52-Week Low
1.31USDUpdated Aug 28, 202652-Week High
19.40USDUpdated Aug 28, 202652-Week Change
-63.86%vs all stocks
Beta
0.9330xvs all stocks
50-Day MA
11.11USDUpdated Aug 28, 2026200-Day MA
12.04USDUpdated Aug 28, 2026Avg 10-Day Volume
7.20MSharesUpdated Aug 28, 2026Avg 30-Day Volume
7.48MSharesUpdated Aug 28, 2026Diluted EPS (TTM)
-1.48USDUpdated Aug 28, 2026Other Income / Expense
-33.00KUSDFY2025 · Dec 31, 20254 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Where is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
Sharp Decline With Volume And Volatility Expansion
A steep fall on heavy volume, leaving the price far below its peak.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.07×)Notable
Debt-to-equity: 0.00Industry median: 0.07Industry P5: 0.00Peers compared: 260
Price-to-book is 0.95×, lower than 95% of its Biotechnology peers (median 2.86×)Notable
Price-to-book: 0.95Industry median: 2.86Industry P5: 0.98Peers compared: 260
Financial Health
Altman Z-Score 1.39: grey zoneSignificant
Altman Z-Score: 1.39
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $81.96M, lower than 95% of all stocks globallySignificant
Market cap (USD): 81,958,378Global P5: 275,556,405.438
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Poolbeg Pharma plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Curiosis Inc.
Tier 1ProductionApproval-Gated PipelineRule
Eco Animal Health Group PLC
Tier 1ProductionApproval-Gated PipelineRule
Creo Medical Group plc
Tier 1ProductionApproval-Gated PipelineRule
Kala Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Bonus BioGroup Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Y-Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Faron Pharmaceuticals Oy
Tier 1ProductionApproval-Gated PipelineRuleRisk
Engene Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRule
Polaryx Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Livewire Group Inc.
4 interpretationsDecline With Range Expansion And DrawdownCash Elevated Relative to Current Liabilities and Total AssetsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedSharp Decline With Volume And Volatility Expansion
Anbio Biotechnology Limited
3 interpretationsDecline With Range Expansion And DrawdownCash Elevated Relative to Current Liabilities and Total AssetsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Wintao Communications Co.
3 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedSharp Decline With Volume And Volatility Expansion